Welcome to the latest issue of Blockbuster Biologics Review, which covers the status and developments of post-grant challenges and patent litigations implicating blockbuster biologics and legislative proposals related to...more
As 2025 unfolds, changes across the patent landscape are unfolding. From agency leadership transitions to proposed legislation and evolving AI-related policies, these shifts could impact patent prosecution, post-grant...more
3/14/2025
/ Artificial Intelligence ,
Corporate Counsel ,
Executive Orders ,
Innovative Technology ,
Inter Partes Review (IPR) Proceeding ,
Legislative Agendas ,
New Legislation ,
Patent Trial and Appeal Board ,
Patents ,
Regulatory Reform ,
USPTO